FDA advisors on Wednesday will deliberate on whether shunt therapy still has a narrow path forward in heart failure after a disappointing pivotal trial. In its premarket approval application for the ...
An experimental transcatheter shunt system that moves blood from the left atrium to the right atrium in patients with heart failure provided even greater benefit at 2 years than in the first year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback